Answers are grounded in this paper and cite their sources.
DNA polymerase theta (Polθ), a multidomain DNA repair enzyme, has emerged as a promising synthetic-lethal target in homologous recombination (HR)-deficient tumors, yet current inhibitors directed at either its helicase or polymerase domain may not fully suppress the functions of the intact protein. Here, we report PR-6, a RNF126-dependent Polθ degrader identified through comparative degrader screening and structural optimization. In BRCA1-deficient MDA-MB-436 cells, PR-6 induced, concentration- and time-dependent Polθ degradation via an RNF126- and ubiquitin-proteasome-dependent mechanism. Compared with the Polθ helicase inhibitor AB25583 under the tested cellular conditions, PR-6 exhibited greater antiproliferative activity and induced more pronounced DNA damage and apoptosis. Moreover, PR-6 synergized with Olaparib in vitro and markedly potentiated its antitumor efficacy in an MDA-MB-436 xenograft model without overt toxicity. These findings support PR-6 as the first degrader probe for interrogating Polθ biology and provide proof of concept for Polθ degradation as a complementary strategy in HR-deficient tumors.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: